You are here:

etelcalcetide (Parsabiv)

Advice

following a full submission assessed under the orphan medicine process:

etelcalcetide (Parsabiv®) is not recommended for use within NHS Scotland.

Indication under review: Treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on haemodialysis therapy.

In a phase III study, etelcalcetide was at least as effective as another calcimimetic in reducing parathyroid hormone levels.

The submitting company did not present a sufficiently robust economic analysis to gain acceptance by the SMC.
This advice takes account of views from a Patient and Clinician Engagement (PACE) meeting.

Drug Details

Drug Name: etelcalcetide (Parsabiv)
SMC Drug ID: 1262/17
Manufacturer: Amgen Ltd
Indication: Treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on haemodialysis therapy.
BNF Category:
Submission Type: Full submission
Status: Not Recommended
Date Advice Published: 11 September 2017

Back